The biotech sector is witnessing significant advancements with Cure Ventures backing Kenai Therapeutics, which has launched with an $82 million investment to develop a cell therapy for Parkinson's disease. This development is part of a broader trend where biotech firms are aiming to revolutionize the treatment of neurological conditions and cancer. Notably, there's a push towards creating therapies that can be readily available off the shelf, enhancing the speed and efficiency of treatment delivery. Additionally, the sector is exploring targeted cancer therapies, including a promising EGFR inhibitor, and antisense technologies for treating ALS and frontotemporal dementia.
Exclusive: Kenai Therapeutics launches with $82 million for #Parkinsons cell therapy. https://t.co/QeGjNw5x9W
💡🔬Antisense technologies have been showing promise as a new way to treat neurodegenerative diseases. @DjuranovicLab + @MillerLabNeuro are building off this innovation by developing a new approach to treat ALS + frontotemporal dementia https://t.co/DNfpbeBDAV
Cure Ventures backs a cell therapy startup targeting Parkinson’s https://t.co/rG72YCipiA by @realJacobBell #Parkinsons
Exclusive: The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to patients is materializing in the cancer world. Now, a new biotech with $82 million hopes to do the same for neurological conditions. https://t.co/EJjNQKZETV
A couple of interesting biotech startup stories this morning: -- Cell therapy for Parkinson's https://t.co/nNn353WC8Q via @ADeAngelis_bio -- Targeted cancer therapy, most interestingly, a potentially better EGFR inhibitor. https://t.co/hpNTE27rdc via @matthewherper